Introduction
"Myeloproliferative disorders (MPDs)" were first defined by William Dameshek in 1951: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). 1 The upcoming revised World
Health Organization (WHO) classification system for hematopoietic tumors included these four classic MPDs in a broader category of "myeloproliferative neoplasms (MPNs)" that includes, in addition, other "non-classic" MPNs: chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), hypereosinophilic syndrome (HES), systemic mastocytosis (SM), and "MPNs, unclassifiable". Both 'classic' and 'non-classic' MPNs as clonal stem cell disorders. 2 The disease causing somatic mutations in these disorders have been identified in some but not others: BCR-ABL in CML,
FIP1L1-PDGFRA and chromosomal translocations involving PDGFRB or FGFR1 in
molecularly-defined myeloid malignancies associated with eosinophilia. 2 In addition, other mutations of potential pathogenetic relevance are in the process of being defined:
SM-associated KIT mutations, JAK2V617F in PV, ET, and PMF; JAK2 exon 12 mutations in PV; and MPLW515L/K in PMF and ET.
2

JAK2V617F and other novel mutations in the classic MPNs
The association of JAK2V617F with MPNs, including PV, ET, and PMF, was first reported in 2005. [3] [4] [5] [6] Since then, the mutation has also been described, at a lower frequency, in a spectrum of other myeloid disorders including non-classic MPNs and other chronic myeloid neoplasms including myelodysplastic syndrome (MDS).
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JAK2V617F is not found in lymphoid disorders, 9-12 solid tumor [13] [14] [15] or secondary myeloproliferation. 16, 17 JAK2V617F is a G to T exon 14 somatic mutation resulting in the substitution of valine to phenylalanine at codon 617. In general, a high JAK2V617F allele burden might be essential for acquisition of the PV phenotype in vivo; this is accomplished by mitotic recombination that leads to homozygosity for JAK2V617F. [3] [4] [5] Unlike the case with JAK2V617F, the other two sets of mutations associated with
MPNs are restricted to patients with PV (JAK2 exon 12 mutations) 18, 19 
New diagnostic approaches in the classic MPNs
True polycythemia may represent either PV or non-clonal erythrocytosis (i.e. secondary polycythemia) that is often, but not always, mediated by erythropoietin (Epo).
Apparent polycythemia (i.e. with normal red cell mass) may result from either a reduction in plasma volume (relative polycythemia) or an inaccurate perception of an elevated erythrocyte volume that results from not appreciating high normal values of hematocrit.
The term "inapparent PV" is used to describe PV patients in whom increased erythrocyte volume is masked by "normal" hematocrit because of a concomitant increase in plasma volume. 22 Therefore, in a suspected case of PV, one has to exclude both secondary and apparent polycythemia whereas the possibility of inapparent PV should be entertained in the presence of PV-characteristic clinical features, regardless of the hematocrit level.
The recent discovery of the almost invariable association between PV and a JAK2 mutation (either JAK2V617F or a JAK2 exon 12 mutation) 23 has led to a revised WHO diagnostic criteria for PV that incorporates JAK2 mutation screening (Table 1) . 24 In routine clinical practice, one should start with both JAK2V617F mutation screening and serum Epo measurement when PV is suspected (Figure 1) . 25, 26 A positive mutation test is highly suggestive of the diagnosis, especially if accompanied by subnormal serum Epo level. Approximately 5% of PV patients are negative for JAK2V617F. 23 Therefore, in a JAK2V617F-negative patient with either a high clinical suspicion of PV or subnormal serum Epo level, the possibility of exon 12 JAK2 mutations should be entertained and pursued.
The 2001 WHO diagnostic criteria for ET and PMF have also been recently revised by the WHO (Tables 2 and 3) . 24 Unlike the case with PV, JAK2V617F mutation screening plays a minor role in the diagnosis of ET and PMF, which is primarily based on bone marrow histology; 27 characteristic changes include hypercellularity, increased number of dysplastic megakaryocytes including cluster formation, and bone marrow stromal changes including myelofibrosis. 28 In general, I also advise baseline bone marrow examination for all patients with PV although the procedure is not essential for making the diagnosis and its prognostic value has not been systematically studied.
Prognosis and treatment of the classic MPNs in the JAK2V617F era
In general, neither the presence of JAK2V617F nor its allele burden has been shown to influence survival or leukemic/fibrotic transformation in ET, PV, or PMF. [29] [30] [31] [32] [33] [34] [35] [36] [37] Similarly, the results of published studies regarding the relationship between thrombosis and JAK2V617F have not been consistent enough to warrant definitive conclusions in that regard. 35 Instead, new information suggests a prognostic value for leukocytosis for overall survival in both ET 34 and PV, 38 for leukemic transformation in PV, 38 and for thrombosis in both PV 38 and ET. 34 In table 4 , I have summarized current risk-adapted treatment strategies in ET, PV, and PMF. Phlebotomy is the only form of treatment modality that is believed to have improved survival in PV patients. In this regard, a recent study has challenged the need for aggressive phlebotomy in aspirin-treated patients with hematocrit that ranges between 40% and 55%. 39 Nevertheless, for now, I recommend keeping the hematocrit level below 45%. In addition, all patients with PV should receive daily low-dose aspirin in the absence of contraindication for aspirin use. 40 The additional benefit of cytoreductive therapy in PV, in terms of reducing thrombosis risk, was suggested by the early PVSG studies. 41 However, the danger of long-term drug-associated complications has restricted their use in high-risk patients only (Table 4 ). At present, hydroxyurea is my drug of choice for use in high-risk patients with PV. The potential value of alfa interferon (α-IFN) therapy requires validation in a controlled setting. 42 It is reasonable to expect near-normal survival in the majority of patients with ET, especially in the absence of leukocytosis, regardless of specific treatment. 34 Furthermore, the relatively low incidence figures of thrombosis and hemorrhage as well as the occurrence of both short-term and long-term drug side effects are the basis for carefully selecting the patients with ET who require specific treatment (Table 4) . In other words, at present, I use cytoreductive therapy in ET only in the presence of risk factors for thrombosis including advanced age (≥ 60 years) or history of major thrombosis. In particular, I do not treat extreme thrombocytosis per se in the absence of aspirin-resistant symptoms. 43 If cytoreductive therapy is indicated, then it is important to note that only hydroxyurea, as a treatment agent, has been shown in a prospective study to be associated with a reduced risk of thrombosis in ET. 44 Hydroxyurea was also found to be superior to anagrelide in a head-to-head comparative study of high-risk patients with ET. 45 The concern regarding hydroxyurea leukemogenicity in ET is currently unsubstantiated 34 and the indiscriminate use of new drugs that are not tested in a controlled setting is unwarranted.
Among the BCR-ABL-negative classic MPNs, PMF has the worst prognosis with an approximate median survival of 5 years. 46 However, several studies have identified both clinical and laboratory parameters that are used to identify good-risk as well as highrisk patient categories. 47 The most important indicators of adverse prognosis are the presence of anemia (hemoglobin < 10 g/dL), advanced age (> 64 years), hypercatabolic symptoms (weight loss, profound fatigue, night sweats, low-grade fever), leukocytosis (>30,000/μL) or leukopenia (<4000/μL), circulating blasts (≥1%), high-risk cytogenetic abnormalities (+8, 12p-), peripheral blood monocyte count of ≥1,000/μL, and platelet count of < 100,000/μL. 46,48-52 Table 4 outlines the Mayo prognostic scoring system for PMF and the corresponding treatment options for each risk category. 50 The presence of del(5q) in intermediate-or high-risk patient with MF warrants a therapeutic trial with lenalidomide. 
53-55
Peripheral blood mutation screening for JAK2V617F
Positive Negative 
